Steven Treon
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Professor Steven Treon is a faculty member at Harvard Medical School in the United States. His research primarily focuses on Waldenström macroglobulinemia, including therapeutic strategies involving BTK inhibitors and genomics. Recent publications include analyses on treatment modalities and molecular subtypes related to this condition.
Articles (27)
Year:
2026
Approximately 20% of patients with Waldenström macroglobulinemia (WM) report family history (FH) of hematologic malignancies. However, the impact of FH on patient outcomes remains unclear. We included 1000 patients with WM to determine the relationship between FH, characteristics, complications, and treatment outcomes. Data collected included clinical features at diagnosis, complications (Bing-Neel syndrome [BNS], aggressive transformation, AL [light chain] amyloidosis, and neuropathy), FH cluster (WM [WM-FH], other B-cell FH [B-FH], non–B-cell FH [NON–B-FH], and sporadic [NO-FH]), and treatment outcomes. Logistic regression models were fitted to estimate the odds of complications. Time-to-event outcomes were assessed using the Kaplan-Meier method, and differences between groups evaluated using the log-rank test. Proportional hazards Cox regression models were fitted to determine the impact of WM-FH on time to first treatment (TTFT), overall survival (OS), and survival after first treatment initiation (SAFTI). The NO-FH group was the reference group for the regression analyses. The median follow-up time from diagnosis was 13 years. There were more women in the WM-FH than in the NO-FH group (50% vs 34%; P< .01). In multivariate logistic regression analysis, WM-FH was associated with higher odds of BNS (odds ratio [OR], 3.90; P = .005) and lower odds of neuropathy (OR, 0.49; P = .03) than NO-FH. The median TTFT was 0.7 years, OS was 23 years, and SAFTI was 20.5 years for all patients. In multivariate Cox regression analyses, WM-FH did not affect TTFT, SAFTI, or OS. Our study suggests higher odds of BNS and lower odds of neuropathy in patients with WM-FH but no impact of WM-FH on TTFT, OS, or SAFTI.
Year:
2026
Year:
2026
Despite recent advances in treatment strategies of Waldenström macroglobulinemia (WM) patients, the disease remains incurable. While several genomic features predict poor outcomes with ibrutinib, the contribution of immune dysfunction to tumor behavior remains unclear. Single-cell RNA sequencing on longitudinal bone marrows from 37 Waldenström macroglobulinemia patients before and after ibrutinib therapy profiled 348,000 cells and identified distinct immune phenotypes associated with ibrutinib progression. This was primarily characterized by the accumulation of T-effector cells, Tregs and pro-inflammatory M1-like monocytes, alongside a depletion of naïve T-cells. The tumor architecture in progressing patients, exhibited a unique transcriptomic signature, also validated in an external cohort of 47 WM patients, driven by genes including LTB, NFKBIA, DUSP2 , NR4A1 leading to shorter progression-free survival. Mutational profiling using whole-genome sequencing identified mutational signature SBS1/SBS5 being significantly associated with poorer outcome. Finally, we demonstrate that integrating tumor with immune cell compartments can significantly improve ibrutinib response prediction scoring.
Year:
2026
Ibrutinib (I) and ibrutinib plus rituximab (I+R) are highly efficacious in treating Waldenström macroglobulinemia (WM). However, the benefit of adding rituximab remains unclear, and a prospective trial to compare these two regimens has not been undertaken. Therefore, we performed a pooled analysis of prospective studies to compare their effectiveness. Patient-level demographic, response, and survival data were pooled from three prospective studies (ClinicalTrials.gov identifiers: NCT01614821, NCT02604511, NCT02165397). We included patients treated with I+R or I, excluding those without MYD88 mutations. Among 174 patients (58 I+R, 116 I), very good partial response (VGPR) rates were comparable across treatment groups (38% I+R vs 28% I; P = .21). The 48-month progression-free survival (PFS) rate was 74% with I+R vs 61% with I (P = .22). The 48-month overall survival rate was 94% vs 89% (P = .45). In patients with CXCR4 mutations, I+R trended toward higher VGPR (27% vs 11%; P = .10), and had a superior 48-month PFS rate (72% vs 43%; P = .03). CXCR4 mutations were associated with inferior VGPR (42% vs 17%; P = .001) and 48-month PFS in the I arm (43% vs 72%; P = .002). In the I+R arm, CXCR4 mutations were associated with numerically inferior VGPR (47% vs 27%; P = .12), but the 48-month PFS rate was not impacted (74% vs 72%; P = .96). I+R significantly improved PFS over I in patients with CXCR4-mutated WM, along with a nonsignificant increase in VGPR in this subgroup. These results support routine CXCR4 testing in patients with WM, and clinical trials of rituximab with covalent or noncovalent Bruton tyrosine kinase inhibitors.
Year:
2025
Year:
2025
Waldenström macroglobulinemia (WM) is an IgM secreting lymphoplasmacytic lymphoma. Mutations in MYD88 (95%–97%) and CXCR4 (30%–40%) are common in patients with WM. TP53 is also altered in up to 30% of WM patients, particularly those previously treated. Mutated MYD88 triggers the expression and activation of HCK that drives multiple pro‐survival signaling cascades, including BTK. There are over 40 CXCR4 mutation types in WM. WM patients bearing nonsense CXCR4 variants can present with symptomatic hyperviscosity and show greater resistance to covalent BTK inhibitors (cBTK‐i). The cBTK‐i zanubrutinib shows greater response activity and/or improved progression‐free survival in WM patients with wild‐type MYD88, mutated CXCR4, or altered TP53. New or emerging options for patients progressing on c‐BTKi include pirtobrutinib, BGB‐16673, venetoclax, and sonrotoclax. Combinations of BTK inhibitors with chemoimmunotherapy and BCL2 antagonists have advanced. Algorithms for patients with treatment‐naïve and previously treated WM based on genomics, disease characteristics, and co‐morbidities are discussed.
Year:
2025
Infiltration of the central nervous system by malignant lymphoplasmacytic cells is a rare complication of Waldenström macroglobulinaemia (WM) and is referred to as Bing–Neel syndrome (BNS). Traditionally, the treatment of BNS included chemotherapy, but in more recent years, the oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib has become a standard therapy for WM and the most common therapy for BNS due to the drugs tolerability and ability to cross the blood–brain barrier. Zanubrutinib, a second‐generation covalent BTK inhibitor with fewer off‐target effects, is also effective in WM. In this series, we report on the successful use of zanubrutinib in nine patients with BNS, of whom five had prior exposure to ibrutinib and four were naïve to BTK inhibitors.
Year:
2025
To study the heterogeneity of transcriptional and genomic traits that underlie the clinical presentation of untreated Waldenstrom’s Macroglobulinemia (WM), we performed multi-omic studies in 249 treatment-naive patients with WM. For all patients, RNASeq was performed on CD19-selected bone marrow (BM) MYD88 mutated samples as well as 13 paired CD19 + CD27 − and CD19 + CD27 + peripheral blood samples from healthy donors. Whole exome sequencing (WES) was also analyzed on paired tumor and germline DNA for 229 of these patients and DNA methylation status was assessed by enhanced reduced representational bisulfite sequencing (ERRBS) for 32 samples. The ERRBS and transcriptional data identified two distinct cells of origin for WM leading to two independent WM subtypes known as B-cell Like (BCL) and Plasma Cell Like (PCL). A third subtype, Early WM, was observed primarily in smoldering WM and was present in both ERRBS clusters identifying it as a transcriptional state common to early BCL and PCL. We further identified the WM Evolutionary Score (EScore), a gene signature common to all samples that predicted time to first therapy and corresponded with progression to symptomatic WM. Analysis of the EScore revealed a subclone expressing pre-B-cell, T-cell, stem cell and myeloid markers that was confirmed by flow cytometry and detected in early (smoldering) WM with subpopulations persisting with WM evolution. Our findings have important implications for WM pathogenesis. The evolution from the Early WM subtype to either BCL or PCL and EScore explains much of the genomic, transcriptional and clinical heterogeneity of WM including clinical outcomes to primary therapy.
Year:
2025
As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However, the impact of depth of response from fixed‐duration therapy on overall survival (OS) was unclear. This multicenter study evaluated the prognostic impact of depth of response using a landmark survival analysis. A total of 440 patients with WM treated with frontline fixed‐duration regimens were included. Attaining a major response (MaR) was associated with superior outcomes, including significantly longer OS. The estimated 5‐year PFS rates for patients with MaR at 6 months versus not were 50% versus 32%, respectively, p < 0.001, and the estimated 5‐year OS rates for patients with MaR at 6 months versus not were 89% versus 70%, respectively, p < 0.001. In a multivariable analysis, MaR at 6 months was independently associated with superior PFS (HR 0.66, p = 0.007) and OS (HR 0.28, p < 0.001). Similar results were seen when considering deeper responses (CR + VGPR vs. PR). Depth of response at 6 months is an important prognostic marker in WM and an independent predictor of PFS and OS. These results support its utilization as a suitable endpoint in clinical studies in WM.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (23)
Meletios Dimopoulos
Professor
National and Kapodistrian University of Athens
Shaji Kumar
Medical College of Wisconsin
Constantine S. Tam
-
Marie José Kersten
University of Amsterdam
Judith Trotman
Head of Department
Concord Repatriation General Hospital
Morie Gertz
Mayo Clinic
Shirong Liu
Senior Scientist
Dana-Farber Cancer Institute
Alain Delmer
Professor of Hematology
-
Angela Dispenzieri
Professor / Consultant
Mayo Clinic Minnesota
Maria Gavriatopoulou
National and Kapodistrian University of Athens
Mehmet Samur
Senior Research Scientist
Dana-Farber Cancer Institute
Marcel Spaargaren
Associate Professor
Academic Medical Center
Carlos Fernandez de Larrea Rodriguez
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Efstathios Kastritis
Professor
National and Kapodistrian University of Athens
Evangelos Terpos
Professor of Hematology
National and Kapodistrian University of Athens - Faculty of Medicine
Ramón García-Sanz
Profesor Titular de Medicina / Hematología
Universidad Complutense de Madrid
Nathanael S. Gray
Stanford University
Monique C. Minnema
-
Jorge Castillo
Clinical Director, Bing Center for Waldenstrom Macroglobulinemia
Dana-Farber Cancer Institute
Tanya Siddiqi
Associate Professor
City Of Hope National Medical Center
Roch Houot
university hospital of Rennes
Jonas Paludo
Assistant Professor of Medicine and Oncology
Mayo Clinic
Ari M. Melnick
Director
Josep Carreras Leukaemia Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.